Do you have redness, watering, or irritation of the eye? You may have adenoviral or bacterial conjunctivitis (pink eye).
Contact us to learn whether you could take part in a research study looking at a potential new drug targeting the two main causes of pink eye.
What is pink eye?
Pink eye is a temporary infection of the conjunctiva (the thin lining that covers the whites of the eyes and the insides of the eyelids) most commonly caused by adenoviruses (a type of virus) or bacteria.
People with pink eye may have signs and symptoms such as redness, watering/discharge, irritation, or soreness of the eyes for a few days or weeks before their symptoms improve.
There are no drugs currently approved to treat pink eye caused by adenoviruses. Antibiotics only work if the infection is caused by bacteria. New drugs that work for both adenoviral and bacterial causes of pink eye are needed to relieve symptoms, speed up recovery, and reduce unnecessary antibiotic use when the cause is an adenovirus.
What are the Synchronize research studies?
The Synchronize research studies are looking at a potential new drug designed to target the two most common causes of pink eye – adenoviral or bacterial infection. By taking part in one of the studies, you and/or your child may have the opportunity to receive a potential new drug for pink eye and to receive specialist care from our study team. You may be reimbursed for your travel expenses.
Who can participate?
Adults and children of any age may be able to take part in a Synchronize research study. You and/or your child may be able to participate if you (or they):
• have had pink eye signs or symptoms (e.g. redness, watering) in at least one eye for no more than the past 3 days
• are interested in taking part in a research study for up to 13 days
• are willing to travel to the study center for appointments
Additional criteria, including some for newborn infants and young babies, may apply.
Would you like to know more?
If you would like more information, please contact us using the details provided below: